Background: The clinical significance of genetic alterations in stage II/III non-small cell lung cancer (NSCLC) patients has not yet been clarified. We have prospectively analyzed NSCLC patients for cancer-related gene alterations and have followed up clinical course of the patients, establishing a large-scale clinico-genomic database in our nationwide genome screening project (LC-SCRUM-Japan)... Conclusions: In stage II/III NSCLC, the total frequency of targetable gene alterations was similar to that previously evaluated in our stage IV cohort (45%), and the current standard therapies showed early progression in the targetable gene-altered patients. A novel effective multimodality treatment in combination with targeted therapies is needed for this population. READ ARTICLE
Journal of Clinical Oncology DOI:10.1200/JCO.2020.38.15_suppl.9038
Authors: Yoshitaka Zenke, Shingo Matsumoto, Terufumi Kato, Shingo Miyamoto, Takuma Imakita, Tetsuya Mitsudomi, Hiromi Aono, Ryota Ushio, Naoki Furuya, Kazumi Nishino, Saori Takata, Mika Nakao, Satoshi Hara, Motoko Tachihara, Akimasa Sekine, Jun Sakakibara-Konishi, Ryo Toyozawa, Kiyotaka Yoh, Koichi Goto